Rallybio (RLYB) News
NASDAQ: RLYBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
15.47-0.05 (-0.32%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RLYB news summary
We found 2 recent headlines mentioning Rallybio (RLYB): 0 in the past week and 2 in the past 30 days, most often from Business Wire, Nasdaq. For price context, RLYB is down 0.32% at $15.47. The most recent story, "Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with Avenzo", was published by Business Wire on Nov 11, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Rallybio headlines
- Correction to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with AvenzoEAST BERLIN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced a correction to its press release issued November 10, 2026. The prior press release incorrectly stated that…Business Wire
- Rallybio Corporation Postpones Merger Closing Originally Scheduled for November 6, 2026Rallybio Corporation announced that the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of May 31, 2026, by and among the Company, Avenzo Therapeutics, Inc.…Nasdaq